Recent Updates
Recently added Catalysts
AGEN Positive Sentiment

Samenvatting: Agenus rapporteert een geschatte driejarige overleving van 48% met BOT+BAL bij recidiverende eierstokkanker tijdens IGCS 2026

Sunday, October 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agenus Inc. has announced a three-year survival rate of 48% for patients with recurrent ovarian cancer in its Phase 1b study C-800-01. The study evaluated the efficacy of botensilimab (BOT) combined with balstilimab (BAL) and involved more than 400 patients. These results highlight the potential of this treatment combination in immuno-oncology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Agenus reports a promising three-year survival rate of 48%.
  • The study involved over 400 patients, indicating robust data.
  • The combination of BOT and BAL shows potential in treating recurrent ovarian cancer.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+121%
120-day peak, hindsight
Typical move
3.1%
average across 3 past catalysts
Cash runway
~0 mo
High dilution risk
Lead asset
Botensilimab
Phase 2 · Colorectal Cancer

Full Press Release Details

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), een toonaangevende speler op het gebied van innovatie in immuno-oncologie, heeft vandaag de resultaten bekendgemaakt van de driejarige follow-up van het cohort met eierstokkankerpatiënten uit zijn fase 1b-studie C-800-01, waaraan meer dan 400 patiënten deelnamen. In het onderzoek werd botensilimab (BOT), het multifunctionele, Fc-versterkte anti-CTLA-4-antilichaam van Agenus, geëvalueerd in combinatie met balstilimab (BAL), het anti-

Frequently Asked Questions

What was the survival rate reported by Agenus?

Agenus reported a three-year survival rate of 48% for patients.

How many patients were involved in the study?

The study involved more than 400 patients.

What treatments were evaluated in the study?

The study evaluated botensilimab (BOT) and balstilimab (BAL).

What type of cancer was the focus of the study?

The study focused on recurrent ovarian cancer.

ShareAdd on Google
Tags: AGEN Agenus ovarian cancer BOT BAL immuno-oncology
Last updated: Oct 4, 2026

Biotech snapshot

Cash runway
$19M liquidity · $10M/mo burn
~0 mo
High dilution risk
Lead asset
BotensilimabPhase 2
Colorectal Cancer →

Catalyst track record

+121%
best trade around AGEN's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for AGEN.

See every catalyst's timing & PoA →